{"totalCount":5,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT05143996","orgStudyIdInfo":{"id":"CLN-049-001"},"secondaryIdInfos":[{"id":"2020-005195-35","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Cullinan Therapeutics Inc.","class":"INDUSTRY"},"briefTitle":"CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","officialTitle":"A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"RECRUITING","startDateStruct":{"date":"2021-11-18","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2027-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-10-26","studyFirstSubmitQcDate":"2021-12-02","studyFirstPostDateStruct":{"date":"2021-12-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-14","lastUpdatePostDateStruct":{"date":"2026-01-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Cullinan Therapeutics Inc.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","detailedDescription":"This trial is divided into 3 parts:\n\nPart A - Single Ascending Dose (SAD) - Patients will receive a single dose of CLN-049 via IV administration and be followed for safety for 28 days\n\nPart B - Multiple Ascending Dose (MAD) - Patients will received CLN-049 every 7 days (q7d) after an initial Lead-In Dose via IV administration and be followed for safety for 28 days and will then enter long-term follow-up for up to 2 years\n\nPart C - Multiple Ascending Dose (MAD) - Patients will receive CLN-049 q7d via SC injection and be followed for safety for 28 days and will then enter long-term follow-up for up to 2 years\n\nThe SC injection cohorts will be initiated first, followed by IV administration cohorts"},"conditionsModule":{"conditions":["Relapsed/Refractory Acute Myeloid Leukemia (AML)","Myelodysplastic Syndrome (MDS)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":60,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Part A - Single ascending dose (SAD) design of IV administered CLN-049","type":"EXPERIMENTAL","description":"Patients with relapsed/refractory AML or MDS will receive CLN-049 via IV administration","interventionNames":["Drug: CLN-049"]},{"label":"Part B - Multiple ascending dose (MAD) design of IV administered CLN-049","type":"EXPERIMENTAL","description":"Patients with relapsed/refractory AML or MDS will receive CLN-049 via IV administration","interventionNames":["Drug: CLN-049"]},{"label":"Part C - Multiple ascending dose (MAD) design of SC administered CLN-049","type":"EXPERIMENTAL","description":"Patients with relapsed/refractory AML or MDS will receive CLN-049 via SC injection","interventionNames":["Drug: CLN-049"]}],"interventions":[{"type":"DRUG","name":"CLN-049","description":"\\[FLT3\\] x \\[CD3\\] bispecific T cell engager","armGroupLabels":["Part A - Single ascending dose (SAD) design of IV administered CLN-049","Part B - Multiple ascending dose (MAD) design of IV administered CLN-049","Part C - Multiple ascending dose (MAD) design of SC administered CLN-049"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of treatment emergent events (TEAEs)","description":"TEAEs will be defined as adverse events that are reported for the first time following study drug administration for worsening of a pre-existing event after the first dose","timeFrame":"28 days"},{"measure":"Cmax of CLN-049","description":"Maximum drug concentration","timeFrame":"28 Days"},{"measure":"Ctrough of CLN-049","description":"The observed plasma concentration just prior to the beginning of, or at the end of a dosing interval","timeFrame":"28 Days"},{"measure":"Tmax of CLN-049","description":"Time to Cmax","timeFrame":"28 Days"},{"measure":"T1/2 of CLN-049","description":"28 Days","timeFrame":"Up to 28 days"}],"secondaryOutcomes":[{"measure":"Immunogenicity of CLN-049","description":"Number of ADA (anti-drug antibodies) positive samples at the end of therapy - minus the number of samples that are positive at baseline","timeFrame":"28 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Aged ≥ 18 years of age.\n2. Willing and able to give written informed consent and adhere to protocol requirements; written informed consent and any locally required authorization must be obtained from the patient prior to performing any protocol-related procedures, including screening evaluations, and serial samples of bone marrow and peripheral blood.\n3. Patient has a confirmed diagnosis of recurrent or refractory AML or MDS.\n4. Patient has received, and has progressed, recurred, or is intolerant of approved therapeutic options that are available, or declines treatment with these therapies.\n5. White blood cell (WBC) count at the time of the first dose is \\< 20,000/uL (hydroxyurea is permitted according to standard institutional practice). Following first dose, WBC should be checked prior to subsequent CLN-049 administration and if WBC \\> 20,000/μL, CLN-049 treatment should be postponed (see Section 6.1 for further guidance).\n6. Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 2.\n7. Toxicities related to prior study therapy should have resolved to Grade 1 or less according to criteria of NCI CTCAE v5.0, except for alopecia, lymphopenia, neutropenia, leukopenia, anemia, thrombocytopenia. Patients with chronic but stable toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.\n8. The patient's laboratory values meet the following criteria:\n\n   1. Creatinine clearance (CrCl) as calculated by the Cockcroft-Gault formula (Appendix 1) must be ≥ 60 mL/min;\n   2. Total bilirubin ≤ 1.5 × ULN. This does not apply for patients with confirmed Gilbert's Syndrome, hemolysis, or chronic blood transfusions, for whom total bilirubin must be less than 3.0 mg/dL with a conjugated bilirubin less than 0.5 mg/dL;\n   3. AST and ALT ≤ 3.0 × ULN (unless attributed to leukemic involvement).\n\nExclusion Criteria:\n\n1. Diagnosis of acute promyelocytic leukemia (APL)\n2. Active central nervous system (CNS) leukemia. For patients with a history of CNS leukemia, a lumbar puncture should be performed during screening to exclude the presence of active CNS involvement.\n3. Isolated extramedullary relapse\n4. Prior organ allograft\n5. Allogeneic hematopoietic transplantation within six months of treatment, or with clinical or laboratory evidence of GVHD, or requiring ongoing treatment with immune suppression within 2 months of the first dose of CLN-049.\n6. Treatment with any of the following:\n\n   1. Radiation therapy (XRT) within 28 days of the first dose of CLN049, or craniospinal XRT within 8 weeks of the first dose of CLN-049, or history of total body irradiation (TBI).\n   2. Prior immunotherapy with checkpoint inhibitors ≤ 42 days prior to the first dose of CLN-049.\n   3. Prior history of chimeric antigen receptor (CAR-T) cell therapy or other modified T cell therapy.\n   4. Anti-leukemic therapy except hydroxyurea for cytoreduction, and intrathecal chemotherapy ≤ 14 days or 5 half-lives, whichever is shorter, prior to the first dose of CLN-049.\n   5. Short-acting hematopoietic growth factors ≤ 7 days prior to the first dose of CLN-049\n   6. Long-acting growth factors ≤ 14 days prior to the first dose of CLN-049.\n   7. Systemic glucocorticoid therapy (except equivalent of \\< 10 mg prednisone daily) or other immune-suppressive drugs ≤ 14 days prior to the first dose of CLN-049 (see separate guidelines for patients who are post allogeneic hematopoietic transplantation). The transient use of corticosteroids for transfusion premedication or the treatment of infusion or transfusion reactions will not be considered for this criterion. Topical corticosteroids and steroid eye drops are allowed, and will not exclude the patient from eligibility.\n   8. Prior treatment with a FLT3-directed bispecific molecule, or a FLT3-targeted antibody.\n7. Currently participating/previously participated in an interventional study and received an investigational drug within 14 days (or five half-lives, whichever is longer) prior to the first dose of CLN-049.\n8. Patients with concomitant second malignancies requiring active treatment in the past 12 months, or if additional therapy is required or anticipated during study participation.\n9. Patients with any active autoimmune disease or a history of known or suspected autoimmune disease, or history of a syndrome that requires systemic corticosteroids or immunosuppressive medications, except for patients with vitiligo, psoriasis (in consultation with the Sponsor), resolved childhood asthma/atopy or autoimmune thyroid disorders on stable thyroid hormone supplementation.\n10. A serious uncontrolled medical disorder that would impair the ability of the patient to receive protocol therapy or whose control may be jeopardized by the complications of this therapy.\n11. Any concurrent condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might compromise patient safety or interfere with the evaluation of the safety of the drug.\n12. Active uncontrolled infection within seven days of first dose of CLN-049. Prophylactic use of systemic antiviral, antibacterial, or antifungal agents for treatment of chronic, controlled infection or as prophylaxis is permitted.\n13. Has a history of, or a positive test for Human Immunodeficiency Virus (HIV) 1/2 or primary immunodeficiency disease such as HIV.\n14. Known history of hepatitis B (with positive testing for either hepatitis B surface antigen \\[HBsAg\\] or hepatitis B core Ab), hepatitis C (HCV) infection (with positive testing for HCV antibody and/or HCV ribonucleic acid \\[RNA\\] in serum), or acute hepatitis A (with positive testing for hepatitis A IgM). Note: patients with chronic HCV with undetectable viral load defined by sustained virologic response 24 weeks (SVR24) after completion of anti-hepatitis C treatment will be eligible. Patients with hepatitis B surface antigen \\[HBsAg\\] or hepatitis B core Ab with negative viral load will be eligible.\n15. Active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection including history of positive SARS-CoV-2 testing without subsequent documentation of negative test results, patients with results that are pending but not yet known, or patients with suspected active infection based on clinical features\n16. History of the following events in conjunction with prior treatment with immunotherapy: Grade 3 or greater neurotoxicity, ocular toxicity, pneumonitis, myocarditis, or colitis; liver dysfunction meeting the laboratory criteria for Hy's Law.\n17. Live virus vaccines within 28 days of the first dose of CLN-049, during treatment, and until the end of last dose of CLN-049.\n18. Woman of child-bearing potential (WOCBP) who is pregnant or breast-feeding, plans to become pregnant within 120 days of last study drug administration, or declines to use an acceptable method to prevent pregnancy during study treatment and for 120 days after the last dose of study drug administration.\n19. Male patient who plans to father a child or donate sperm within 120 days of last study drug administration, or who has a partner who is a WOCBP, and declines to use acceptable method to prevent pregnancy during study treatment and for 120 days after the last dose of study drug administration.\n20. QT interval corrected for heart rate using Fridericia's formula (QTcF) of ≥ 480 milliseconds.\n21. Patient has history of drug-related anaphylactic reactions to any components of CLN-049. History of Grade 4 anaphylactic reaction to any bispecific molecule or monoclonal antibody therapy.\n22. Known history of prior human anti-human antibody response. Patients will not be screened for human anti-human antibody prior to study participation.\n23. Known active alcohol or drug abuse.\n24. Patients who are incapacitated or involuntarily incarcerated.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Timna Serino","role":"CONTACT","phone":"+1 617 410 4650","email":"ClinOps@cullinantx.com"}],"locations":[{"facility":"University of Alabama O'Neal Cancer Center","status":"RECRUITING","city":"Birmingham","state":"Alabama","zip":"35233","country":"United States","contacts":[{"name":"Anne C Durena","role":"CONTACT","phone":"205-801-9034","email":"accoicoudurena@uabmc.edu"},{"name":"Kimo Bachiashvili, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"UCLA","status":"RECRUITING","city":"Los Angeles","state":"California","zip":"90095","country":"United States","contacts":[{"name":"Bruck Habtemariam","role":"CONTACT","email":"BHabtemariam@mednet.ucla.edu"},{"name":"Gary Schiller","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"University of Miami Health System","status":"RECRUITING","city":"Miami","state":"Florida","zip":"33136","country":"United States","contacts":[{"name":"Jennifer Posada","role":"CONTACT","phone":"305-243-2647","email":"jxp2320@med.miami.edu"},{"name":"Namrata Chandhok, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Moffitt Cancer Center","status":"RECRUITING","city":"Tampa","state":"Florida","zip":"33612","country":"United States","contacts":[{"name":"Fernando Bustamante","role":"CONTACT","email":"Fernando.Bustamante@moffitt.org"},{"name":"Onyee Chan","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Emory University Hospital","status":"RECRUITING","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","contacts":[{"name":"Lindsey E. Overman","role":"CONTACT","email":"lindsey.e.overman@emory.edu"},{"name":"William Blum","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Massachusetts General Hospital","status":"COMPLETED","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Roswell Park Cancer Institute","status":"RECRUITING","city":"Buffalo","state":"New York","zip":"14263","country":"United States","contacts":[{"name":"Wendy Walinski","role":"CONTACT","phone":"1-800-767-9355","email":"wendy.walinski@roswellpark.org"},{"name":"Eunice Wang, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":42.88645,"lon":-78.87837}},{"facility":"New York University","status":"RECRUITING","city":"New York","state":"New York","zip":"10016","country":"United States","contacts":[{"name":"Rachel Joseph","role":"CONTACT","email":"Rachel.Joseph@nyulangone.org"},{"name":"Mohammad Maher Abdul Hay","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Duke Cancer Center","status":"RECRUITING","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","contacts":[{"name":"Samuel Dell","role":"CONTACT","phone":"919-681-5698","email":"samuel.dell@duke.edu"},{"name":"Sanghee Hong, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Cincinnati Children's Hospital Medical Center","status":"WITHDRAWN","city":"Cincinnati","state":"Ohio","zip":"45229","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"MD Anderson","status":"RECRUITING","city":"Houston","state":"Texas","zip":"77030","country":"United States","contacts":[{"name":"Allison Pike","role":"CONTACT","email":"APike@mdanderson.org"},{"name":"Ghayas Issa","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":29.76328,"lon":-95.36327}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D015470","term":"Leukemia, Myeloid, Acute"},{"id":"D009190","term":"Myelodysplastic Syndromes"}],"ancestors":[{"id":"D007951","term":"Leukemia, Myeloid"},{"id":"D007938","term":"Leukemia"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D001855","term":"Bone Marrow Diseases"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06381141","orgStudyIdInfo":{"id":"CLN-619-002"},"organization":{"fullName":"Cullinan Therapeutics Inc.","class":"INDUSTRY"},"briefTitle":"A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma","officialTitle":"A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-09-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-09","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-04-02","studyFirstSubmitQcDate":"2024-04-19","studyFirstPostDateStruct":{"date":"2024-04-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-12","lastUpdatePostDateStruct":{"date":"2025-09-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Cullinan Therapeutics Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma"},"conditionsModule":{"conditions":["Multiple Myeloma"],"keywords":["Relapsed and Refractory Multiple Myeloma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":30,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Part 1 Dose Escalation","type":"EXPERIMENTAL","description":"Cohorts of patients with R/R MM will be treated at ascending doses of CLN-619 using a standard 3+3 dose escalation design.","interventionNames":["Drug: CLN-619"]}],"interventions":[{"type":"DRUG","name":"CLN-619","description":"Anti-MICA/MICB monoclonal antibody","armGroupLabels":["Part 1 Dose Escalation"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Proportion of participants reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"Incidence of AEs and SAEs using MedDRA","timeFrame":"baseline through 3-week treatment period"},{"measure":"Changes in Eastern Cooperative Oncology Group (ECOG) performance","description":"ECOG Scores are a functional scale ranging from 0 (Fully active, able to carry out all pre-disease activities without restrictions) to 5 (Death)","timeFrame":"Up to 2 years"},{"measure":"Incidence of Dose-Limiting toxicity (DLTs)","description":"Maximum Tolerated Dose (MTD) is reached if 2 or more patients experience a DLT at a dose level","timeFrame":"up to 2 years"},{"measure":"Best Overall Response (BOR) per patient","description":"The best response defined by the International Myeloma Working Group (IMWG) criteria recorded throughout the study including unscheduled assessments","timeFrame":"up to 2 years"},{"measure":"Overall Response Rate (ORR)","description":"The proportion of patients who achieve a partial response or better (e.g., Partial Response (PR), Very Good Partial Response (VGPR), Complete Response (CR) or stringent Complete Response (sCR), according to IMWG response criteria","timeFrame":"up to 2 years"},{"measure":"Duration of Response (DoR)","description":"The time from the earliest date of documented response to the first documented disease progression or death, whichever occurs first.","timeFrame":"up to 2 years"},{"measure":"Clinical Benefit Rate (CBR)","description":"The proportion of patients with a best overall response of CR, PR and stable disease (SD), according to IMWG response criteria","timeFrame":"up to 2 years"},{"measure":"Progression Free Survival (PFS)","description":"The time from date of first dose until the earliest date of disease progression, or death from any cause, whichever occurs first.","timeFrame":"up to 2 years"},{"measure":"Overall Survival (OS)","description":"Time from the date of first dose to date of death due to any cause.","timeFrame":"up to 2 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Aged ≥ 18 years at the time of signing the ICF.\n2. Willing and able to give written informed consent and adhere to protocol requirements.\n3. Patient has a history of multiple myeloma with relapsed and refractory disease as defined by the protocol.\n4. Patients must have measurable disease (as determined by the local laboratory) as defined by the protocol.\n5. Performance status of 0 to 2 based on the Eastern Cooperative Oncology Group (ECOG) performance scale.\n6. Estimated life expectancy of 12 weeks or longer.\n7. Prior palliative radiotherapy must have been completed at least 14 days prior to dosing on Cycle 1 Day 1.\n8. Toxicities related to prior study therapy should have resolved to Grade 1 or less according to criteria of NCI CTCAE v5.0, except for alopecia. Patients with chronic but stable Grade 2 toxicities may be allowed to enroll after an agreement between the Investigator and Sponsor.\n9. Have adequate liver and kidney function and hematological parameters within a normal range as defined by the protocol.\n\nExclusion Criteria:\n\n1. Patient has symptomatic central nervous system involvement of MM.\n2. Patient has nonsecretory MM, plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis.\n3. Patient had a prior autologous stem cell transplant ≤ 3 months prior to first dose of study drug on Cycle 1 Day 1.\n4. Patient had a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 6 months prior first dose of study drug on Cycle 1 Day 1 or is on systemic immunosuppression for graft-versus-host disease.\n5. Patients with concomitant second malignancies (Except adequately treated non-melanomatous skin cancers, ductal carcinoma in situ, superficial bladder cancer, prostate cancer, Grade 1 stage 1A/1B endometrioid endometrial cancer or cervical cancer in situ) are excluded unless in complete remission three years prior to study entry, and no additional therapy is required or anticipated to be required during study participation.\n6. Patients with any active autoimmune disease or a history of known or suspected autoimmune disease, or history of a syndrome that requires systemic corticosteroids treatment or immunosuppressive medications, except for patients with vitiligo, resolved childhood asthma/atopy or autoimmune thyroid disorders on stable thyroid hormone supplementation.\n7. A serious uncontrolled medical disorder that would impair the ability of the patient to receive protocol therapy or whose control may be jeopardized by the complications of this therapy.\n8. Treatment with systemic antiviral, antibacterial or antifungal agents for acute infection within ≤ 7 days of first dose of study drug on Cycle 1 Day 1.\n9. Patient has active peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the NCI-CTCAE v5.0.\n10. Diagnosed with HIV, Hepatitis B, or Hepatitis C infection.\n11. Treatment with non-oncology vaccines for the control of infectious diseases (i.e., HPV vaccine) within 28 days of first dose of study drug on Cycle 1 Day 1.\n12. Active SARS-CoV-2 infection based on positive SARS-CoV-2 test within 4 weeks prior to enrollment or patients with suspected active infection based on clinical features or pending results.\n13. Has received immunosuppressive medications including but not limited to CellCept, methotrexate, infliximab, anakinra, tocilizumab, cyclosporine, or corticosteroids (≥ 10 mg/day of prednisone or equivalent), within 28 days of first dose of study drug on Cycle 1 Day 1.\n14. Patient has history of drug-related anaphylactic reactions to any components of CLN-619. History of Grade 4 anaphylactic reaction to any monoclonal antibody therapy.\n15. Certain treatment with investigational agents and other anti-neoplastic therapy as defined by the protocol\n16. Female of child-bearing potential (FOCBP) who is pregnant or breast-feeding, plans to become pregnant within 120 days of last study drug administration or declines to use an acceptable method to prevent pregnancy during study treatment and for 120 days after the last dose of study drug administration.\n17. Male patients who plans to father a child or donate sperm within 120 days or 5 half-lives of CLN-619, whichever comes later, of last study drug administration, or who has a partner who is a FOCBP, and declines to use an acceptable method to prevent pregnancy during study treatment and for 120 days or 5 half-lives of CLN-619, whichever comes later, after the last dose of study drug administration.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Mayo Clinic","city":"Phoenix","state":"Arizona","zip":"85054","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Mayo Clinic","city":"Jacksonville","state":"Florida","zip":"32224","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Mayo Clinic","city":"Rochester","state":"Minnesota","zip":"55905","country":"United States","geoPoint":{"lat":44.02163,"lon":-92.4699}},{"facility":"Mt. Sinai","city":"New York","state":"New York","zip":"10029","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Memorial Sloan Kettering (MSK)","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Levine Cancer Institute","city":"Charlotte","state":"North Carolina","zip":"28204","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Levine Cancer Institute","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"University of Texas Southwestern Medical Center","city":"Dallas","state":"Texas","zip":"75390","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D009101","term":"Multiple Myeloma"},{"id":"D012008","term":"Recurrence"}],"ancestors":[{"id":"D054219","term":"Neoplasms, Plasma Cell"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D020141","term":"Hemostatic Disorders"},{"id":"D014652","term":"Vascular Diseases"},{"id":"D002318","term":"Cardiovascular Diseases"},{"id":"D010265","term":"Paraproteinemias"},{"id":"D001796","term":"Blood Protein Disorders"},{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D006474","term":"Hemorrhagic Disorders"},{"id":"D008232","term":"Lymphoproliferative Disorders"},{"id":"D007160","term":"Immunoproliferative Disorders"},{"id":"D007154","term":"Immune System Diseases"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT05117476","orgStudyIdInfo":{"id":"CLN-619-001"},"organization":{"fullName":"Cullinan Therapeutics Inc.","class":"INDUSTRY"},"briefTitle":"A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors","officialTitle":"A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors","acronym":"MICA"},"statusModule":{"statusVerifiedDate":"2025-10","overallStatus":"ACTIVE_NOT_RECRUITING","startDateStruct":{"date":"2021-10-29","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-09-02","studyFirstSubmitQcDate":"2021-11-02","studyFirstPostDateStruct":{"date":"2021-11-11","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-11-19","lastUpdatePostDateStruct":{"date":"2025-11-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Cullinan Therapeutics Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors."},"conditionsModule":{"conditions":["Advanced Solid Tumor","NSCLC"],"keywords":["NSCLC","CLN-619","MICA"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":440,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Module A Dose Escalation","type":"EXPERIMENTAL","description":"Patients with advanced solid tumors enrolled in dose escalation cohorts treated with CLN-619","interventionNames":["Drug: CLN-619"]},{"label":"Module A Cohort Expansion","type":"EXPERIMENTAL","description":"Patients with select solid tumor types enrolled in expansion cohorts treated with CLN-619 at a dose selected from the Module A Escalation arm","interventionNames":["Drug: CLN-619"]},{"label":"Module B Combination Therapy Dose Escalation","type":"EXPERIMENTAL","description":"Patients with advanced solid tumors enrolled in dose escalation cohorts treated with CLN-619 in combination with pembrolizumab","interventionNames":["Drug: CLN-619","Drug: Pembrolizumab"]},{"label":"Module B Combination Therapy Cohort Expansion","type":"EXPERIMENTAL","description":"Patients with select tumor types enrolled in expansion cohorts treated with CLN-619 at a dose selected from the Module B Escalation arm, in combination with pembrolizumab","interventionNames":["Drug: CLN-619","Drug: Pembrolizumab"]},{"label":"Module C Escalation and Expansion","type":"EXPERIMENTAL","description":"Patients with select tumor types taking CLN-619 in combination with chemotherapy","interventionNames":["Drug: CLN-619","Drug: Paclitaxel","Drug: Carboplatin AUC 6","Drug: pemetrexed"]},{"label":"Module D Loading Dose","type":"EXPERIMENTAL","description":"Patients with select tumor types taking a loading dose of CLN-619","interventionNames":["Drug: CLN-619"]},{"label":"Module E Safety Run-in and Expansion","type":"EXPERIMENTAL","description":"Patients with select NSCLC tumor types taking CLN-619 in combination with Dato-DXd","interventionNames":["Drug: CLN-619","Drug: Datopotamab deruxtecan-dlnk (Dato-DXd)"]}],"interventions":[{"type":"DRUG","name":"CLN-619","description":"Anti-MICA/MICB monoclonal antibody","armGroupLabels":["Module A Cohort Expansion","Module A Dose Escalation","Module B Combination Therapy Cohort Expansion","Module B Combination Therapy Dose Escalation","Module C Escalation and Expansion","Module D Loading Dose","Module E Safety Run-in and Expansion"]},{"type":"DRUG","name":"Pembrolizumab","description":"Keytruda","armGroupLabels":["Module B Combination Therapy Cohort Expansion","Module B Combination Therapy Dose Escalation"]},{"type":"DRUG","name":"Paclitaxel","description":"Taxane","armGroupLabels":["Module C Escalation and Expansion"]},{"type":"DRUG","name":"Carboplatin AUC 6","description":"Platinum compound","armGroupLabels":["Module C Escalation and Expansion"]},{"type":"DRUG","name":"pemetrexed","description":"antifolate","armGroupLabels":["Module C Escalation and Expansion"]},{"type":"DRUG","name":"Datopotamab deruxtecan-dlnk (Dato-DXd)","description":"TROP-2 antibody-drug conjugate (ADC)","armGroupLabels":["Module E Safety Run-in and Expansion"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Dose Escalation: TEAEs","description":"Number of treatment-emergent events (TEAEs)\n\nTEAE is defined as adverse events reported for the first time or worsening of a pre-existing event after the first dose of study drug.","timeFrame":"24 Months"},{"measure":"Dose Expansion: Best Overall Response (BOR)","description":"The percentage of patients having a CR or PR as determined by PI assessment of disease response per RECIST 1.1 on at least one scan.","timeFrame":"Every 6 weeks for the first 18 weeks and then every 9 weeks until disease progression; approximately 36 months"},{"measure":"Dose Expansion: Overall Response Rate (ORR)","description":"The percentage of patients having a CR or PR as determined by PI assessment of disease response per RECIST 1.1.","timeFrame":"Every 6 weeks for the first 18 weeks and then every 9 weeks until disease progression; approximately 36 months"},{"measure":"Dose Expansion: Duration of Response (DoR)","description":"The time from the earliest date of CR or PR until the earliest date of disease progression, as determined by PI assessment of disease response per RECIST 1.1 or death from any cause if occurring sooner than progression.","timeFrame":"Every 6 weeks for the first 18 weeks and then every 9 weeks until disease progression; approximately 36 months"},{"measure":"Dose Expansion: Disease Control Rate (DCR)","description":"The percentage of participants having CR, PR, or SD as best on study response.","timeFrame":"Every 6 weeks for the first 18 weeks and then every 9 weeks until disease progression; approximately 36 months"},{"measure":"Dose Expansion: Overall Survival (OS)","description":"Time from the initial date of treatment until death.","timeFrame":"Every 6 weeks for the first 18 weeks and then every 9 weeks until disease progression; approximately 36 months"},{"measure":"Dose Expansion: Clinical Benefit Rate (CBR)","description":"The percentage of participants who achieve CR, PR or SD for a duration of 6 months as determined by PI assessment of disease response per RECIST 1.1.","timeFrame":"Every 6 weeks for the first 18 weeks and then every 9 weeks until disease progression; approximately 36 months"}],"secondaryOutcomes":[{"measure":"All Cohorts: Cmax","description":"Maximum drug concentration (Cmax) of CLN-619","timeFrame":"Up to 2 years"},{"measure":"All Cohorts: AUC","description":"Area under the curve up to tau (AUCtau) of CLN-619","timeFrame":"Up to 2 years"},{"measure":"All Cohorts: Time to Maximum concentration","description":"Time to Cmax (Tmax) of CLN-619","timeFrame":"Up to 2 years"},{"measure":"All Cohorts: Clast","description":"Last validated plasma concentration (Clast) of CLN-619","timeFrame":"Up to 2 years"},{"measure":"All Cohorts: Time to last plasma concentration","description":"Time to Clast (Tlast) of CLN-619","timeFrame":"Up to 2 years"},{"measure":"All Cohorts: Half-life","description":"Terminal Half-life (t1/2) of CLN-619","timeFrame":"Up to 2 years"},{"measure":"All Cohorts: Volume of Distribution","description":"Volume of Distribution (V) of CLN-619","timeFrame":"Up to 2 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Males or females aged ≥ 18 years.\n2. Willing and able to give written informed consent and adhere to protocol requirements; written informed consent and any locally required authorization must be obtained from the patient prior to performing any protocol-related procedures, including screening evaluations.\n3. Module A Monotherapy Dose Escalation Cohort and Module B Combination Therapy Dose Escalation Cohorts: Histologically or cytologically-confirmed metastatic or locally advanced, unresectable solid tumors. For Module B, tumor type is listed as an approved indication per the current prescribing information for pembrolizumab.\n4. Module A Cohort Expansions:\n\n   1. Expansion A1: Histologically or cytologically-confirmed metastatic or locally advanced, unresectable NSCLC;\n   2. Expansion A2: Histologically or cytologically-confirmed metastatic or locally advanced, unresectable cervical cancer.\n   3. Expansion A3 and A4: Histologically or cytologically-confirmed metastatic or locally advanced, unresectable endometrial cancer.\n   4. Eligibility for disease-specific expansion cohorts may be further refined by histologic subtype, molecular features, or exposure to prior therapy based on clinical, pharmacodynamic, or biomarker data emerging from the study.\n5. Module B Cohort Expansions:\n\n   1. Expansion B1: Histologically or cytologically-confirmed metastatic or locally-advanced, unresectable NSCLC.\n   2. Expansion B2: Histologically or cytologically-confirmed metastatic or locally-advanced, unresectable endometrial.\n   3. Eligibility for disease-specific expansion cohorts may be further refined by histologic subtype, molecular features, or exposure to prior therapy based on clinical, pharmacodynamic, or biomarker data emerging from the study.\n6. Module C CLN-619 + Chemotherapy Combination Therapy, Escalation and Expansion Cohort\n\n   1. C1: Histologically or cytologically confirmed metastatic or locally advanced, unresectable EGFRm NSCLC.\n   2. C2: Histologically or cytologically confirmed metastatic or locally advanced, unresectable endometrial cancer.\n   3. C3: Histologically or cytologically confirmed metastatic or locally advanced, unresectable, platinum-resistant epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer).\n   4. Eligibility for disease-specific expansion cohorts may be further refined by histologic subtype, molecular features, or exposure to prior therapy based on clinical, pharmacodynamic, or biomarker data emerging from the study.\n7. Module D Loading Dose Cohort:\n\n   a) Tumor types are restricted to epithelial ovarian (including fallopian tube and primary peritoneal), breast, and gastrointestinal (esophageal, gastric, colorectal).\n8. Module E CLN-619 + Dato-DXd Combination Therapy, Safety Run-in and Expansion Cohorts:\n\n   1. Histologically or cytologically confirmed recurrent metastatic or locally advanced, unresectable EGFRm NSCLC.\n   2. Local testing for determination of the mutation status is required.\n9. Prior treatment history as follows:\n\n   1. Patients should have received any other approved standard therapy that is available to the patient, unless this therapy is contraindicated, intolerable to the patient, or is declined by the patient. In the case of a patient declining such therapy, documentation that the patient has been informed and declined should be documented in the medical record.\n   2. Patients eligible for Module E must meet the following criteria: Have received up to 4 prior lines of therapy, including i. Platinum-based chemotherapy ii. At least 1 EGFRm-directed targeted therapy iii. If EGFR T790M, must have received prior osimertinib iv. Prior treatment with topoisomerase I-targeted chemotherapeutic agent or TROP2-directed therapy not allowed\n10. At baseline, patients are required to have one or more measurable lesions that meet RECIST v1.1 and meet the following conditions:\n\n    1. A non-lymph node lesion that has a longest unidimensional measurement of ≥ 10 mm or a lymph node lesion that has a shortest unidimensional measurement of ≥ 15 mm;\n    2. Lesions that have received previous local treatment, such as radiotherapy or ablation, can also be used as measurable target lesions if progression has been confirmed according to RECIST v1.1 prior to enrollment, and the longest unidimensional measurement is ≥ 10 mm.\n11. Performance status of 0 or 1 based on the Eastern Cooperative Oncology Group (ECOG) performance scale.\n12. Estimated life expectancy of 12 weeks or greater.\n13. Prior palliative radiotherapy must have been completed 14 days prior to dosing on C1D1.\n14. Toxicities related to prior study therapy should have resolved to Grade 1 or less according to criteria of NCI CTCAE v5.0, except for alopecia. Peripheral neuropathy should be clinically stable or improving and be Grade 2 or less in severity. Patients with chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.\n15. Have adequate liver and kidney function and hematological parameters within a normal range as defined by:\n\n    1. Total bilirubin ≤ 1.5x ULN. This does not apply for patients with confirmed Gilbert's Syndrome, for whom total bilirubin must be less than 3.0 mg/dL with a conjugated bilirubin less than 0.5 mg/dL;\n    2. AST and ALT ≤ 2.5x ULN or ≤ 5x ULN for patients with liver metastases;\n    3. Creatinine clearance (CrCl) ≥ 45 mL/min as measured or estimated using Cockcroft-Gault formula or serum creatinine \\< 1.5 x ULN;\n    4. Hemoglobin ≥ 9 g/dL without blood transfusions for at least two weeks prior to dosing on C1D1;\n    5. Absolute neutrophil count ≥ 1500 cells/mm3 without growth factor support, three days for filgrastim, 14 days for pegfilgrastim;\n    6. Platelet count ≥ 100,000 cells/mm3.\n16. Patients in the Module A, B, and C dose-escalation cohorts and Module D must have archival tissue available for biomarker analysis. A fresh biopsy is required if archival tissue (e.g., all tumor blocks are exhausted) is unavailable.\n\n    1. Patients participating in the Module A or Module D dose-level cohort extension(s) must agree to provide a fresh biopsy and an on-treatment biopsy at Cycle 2, Day 8.\n    2. Patients in the expansion cohorts for Modules A, B, and C must agree to provide a fresh pretreatment biopsy and an on-treatment biopsy at Cycle 2, Day 8.\n    3. Patients participating in Module E safety run-in and expansion cohorts must provide archival tissue. Pre-treatment fresh biopsies are preferred but not required. On-treatment biopsies are not required.\n\nExclusion Criteria:\n\n1. Currently participating/previously participated in an interventional study and received an investigational drug within 28 days (or five half-lives, whichever is longer) of dosing on C1D1.\n2. Patients with concomitant second malignancies (except adequately treated non-melanomatous skin cancers, ductal carcinoma in situ, superficial bladder cancer, prostate cancer or in situ cervical cancer) are excluded unless in complete remission three years prior to study entry, and no additional therapy is required or anticipated to be required during study participation.\n3. Patients with any active autoimmune disease or a history of known or suspected autoimmune disease, or history of a syndrome that requires systemic corticosteroids or immunosuppressive medications, except for patients with vitiligo, resolved childhood asthma/atopy or autoimmune thyroid disorders on stable thyroid hormone supplementation.\n4. A serious uncontrolled medical disorder that would impair the ability of the patient to receive protocol therapy or whose control may be jeopardized by the complications of this therapy. These criteria include, but are not limited to the following:\n\n   1. Uncontrolled airway hyper-reactivity;\n   2. Type 1 diabetes mellitus. Type 2 diabetes mellitus patients are allowed if they are under stable glycemic control as per Investigator assessment;\n   3. Uncontrolled, clinically significant pulmonary disease;\n   4. Requirement for supplemental oxygen to maintain a pulse ox \\> 93%;\n   5. Symptomatic congestive heart failure as per Investigator assessment or documented cardiac ejection fraction less than 45%;\n   6. Ejection fraction \\< 45% in patients with prior history of treatment with anthracycline chemotherapy or with a prior history of cardiac ventricular dysfunction;\n   7. History of unstable angina or myocardial infarction within six months of dosing on C1D1;\n   8. Unstable cardiac arrhythmia;\n   9. History of ventricular arrhythmia;\n   10. Uncontrolled hypertension: patients with sustained systolic blood pressure readings greater than 150 or diastolic blood pressure greater than 100 should have documentation by treating physician that the finding is not consistent with uncontrolled hypertension;\n   11. History of stroke or cerebral hemorrhage within one year of dosing on C1D1;\n   12. Poorly controlled seizure disorder;\n   13. Active diverticulitis within one year prior to dosing on C1D1;\n   14. Recent major surgery within three months of dosing on C1D1 or major surgery with unresolved complications that could interfere with study treatment.\n   15. Clinically significant corneal disease (Module E).\n5. Treatment with systemic antiviral, antibacterial or antifungal agents for acute infection within ≤ 7 days of dosing on C1D1.\n6. Has known human immunodeficiency virus (HIV) infection that is not well controlled.\n7. Diagnosed with hepatitis B (with positive testing for either hepatitis B surface antigen \\[HBsAg\\] or hepatitis B core Ab) or hepatitis C virus (HCV) infection (with positive testing for HCV antibody and/or HCV ribonucleic acid \\[RNA\\] in serum) under any of the following conditions:\n\n   1. Active disease for hepatitis B or hepatitis C and received antiretroviral therapy within 4 weeks.\n   2. Blood hepatitis B DNA or HCV RNA are detectable.\n8. Prior organ allograft or allogeneic hematopoietic transplantation.\n9. History of the following events in conjunction with prior treatment with checkpoint inhibitor immunotherapy: Grade 3 or greater neurotoxicity, ocular toxicity, pneumonitis, myocarditis, or colitis; liver dysfunction meeting the laboratory criteria for Hy's Law.\n10. Symptomatic uncontrolled brain metastases, known or suspected leptomeningeal metastases and/or carcinomatous meningitis.\n11. Receipt of live vaccine \\< 28 days prior to study start. Treatment with non-oncology recombinant or inactivated vaccines for the control of infectious diseases may be administered according to institutional policy.\n12. Active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based on positive SARS-CoV-2 testing or patients with suspected active infection based on clinical features, including patients with history of SARS-CoV-2-related pneumonitis with 28 days prior to enrollment or patients who have clinically significant pulmonary symptoms related to prior pneumonitis.\n13. Has received immunosuppressive medications including but not limited to cellcept, methotrexate, infliximab, anakinra, tocilizumab, cyclosporine or corticosteroids (≥10 mg/day of prednisone or equivalent), within 14 days of dosing on C1D1.\n14. Woman of child-bearing potential (WOCBP) who is pregnant or breast-feeding, plans to become pregnant within 120 days of last study drug administration, or declines to use an acceptable method to prevent pregnancy during study treatment and for 120 days after the last dose of study drug administration.\n15. Male patient who plans to father a child or donate sperm within 120 days or 5 half-lives of CLN-619, whichever comes later, of last study drug administration, or who has a partner who is a WOCBP, and declines to use acceptable method to prevent pregnancy during study treatment and for 120 days or 5 half-lives of CLN-619, whichever comes later, after the last dose of study drug administration.\n16. QT interval corrected for heart rate using Fridericia's formula (QTcF) of ≥ 500 milliseconds.\n17. Patient has history of drug-related anaphylactic reactions to any components of CLN-619 or combination agent, including hypersensitivity of drugs with similar structure or class. History of Grade 4 anaphylactic reaction to any monoclonal antibody therapy.\n18. Known active alcohol or drug abuse.\n19. Inability to comply with the protocol and/or not willing or not available for follow-up assessments.\n20. Patients who are incapacitated or involuntarily incarcerated.\n21. Patients who are unsuitable for participation based on the judgement of the Investigator.\n22. Treatment with any of the following:\n\n    1. Systemic anticancer treatment within 14 days prior to the first dose of study drug on C1D1.\n    2. Immunotherapy ≤ 28 days prior to the first dose of study drug on C1D1.\n    3. Systemic radiotherapy ≤28 days and local and palliative radiation ≤ 14 days prior to the first dose of study drug on C1D1. I\n    4. Major surgery (excluding placement of vascular access) ≤ 28 days of the first dose of study drug on C1D1.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"University of Alabama at Birmingham","city":"Birmingham","state":"Alabama","zip":"35233","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"City of Hope","city":"Duarte","state":"California","zip":"91010","country":"United States","geoPoint":{"lat":34.13945,"lon":-117.97729}},{"facility":"City of Hope","city":"Irvine","state":"California","zip":"92618","country":"United States","geoPoint":{"lat":33.66946,"lon":-117.82311}},{"facility":"Florida Cancer Specialists","city":"Sarasota","state":"Florida","zip":"34232","country":"United States","geoPoint":{"lat":27.33643,"lon":-82.53065}},{"facility":"Dana-Farber Cancer Institute","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"START Midwest","city":"Grand Rapids","state":"Michigan","zip":"49546","country":"United States","geoPoint":{"lat":42.96336,"lon":-85.66809}},{"facility":"Hackensack Meridian Health","city":"Hackensack","state":"New Jersey","zip":"07601","country":"United States","geoPoint":{"lat":40.88593,"lon":-74.04347}},{"facility":"Memorial Sloan Kettering Cancer Center","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Carolina BioOncology Institute","city":"Huntersville","state":"North Carolina","zip":"28078","country":"United States","geoPoint":{"lat":35.41069,"lon":-80.84285}},{"facility":"Sarah Cannon Research Institute","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"START San Antonio","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Virginia Cancer Center","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"facility":"Monash Health","city":"Clayton","state":"Victoria","zip":"3168","country":"Australia","geoPoint":{"lat":-37.91667,"lon":145.11667}},{"facility":"Alfred Health","city":"Melbourne","state":"Victoria","zip":"3004","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"Linear Clinical Research","city":"Nedlands","state":"Western Australia","zip":"6009","country":"Australia","geoPoint":{"lat":-31.98184,"lon":115.8073}},{"facility":"Biokinetica","city":"Józefów","zip":"05-410","country":"Poland","geoPoint":{"lat":52.13707,"lon":21.23589}},{"facility":"Med-Polonia Sp. zo. o.","city":"Poznan","zip":"60-693","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Narodowy Insytut Onkologii im Marii Sklodowskiej-Curie","city":"Warsaw","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Hospital Universitario Insular de Gran Canaria","city":"Las Palmas de Gran Canaria","state":"Gran Canaria","zip":"35016","country":"Spain","geoPoint":{"lat":28.10178,"lon":-15.41573}},{"facility":"START Barcelona","city":"Barcelona","zip":"08023","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Clinic Barcelona","city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"START Madrid FJD","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Clinica Universidad de Navarra","city":"Pamplona","zip":"31008","country":"Spain","geoPoint":{"lat":42.81687,"lon":-1.64323}},{"facility":"Hospital Universitari Parc Tauli","city":"Sabadell","zip":"08208","country":"Spain","geoPoint":{"lat":41.54329,"lon":2.10942}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"interventionBrowseModule":{"meshes":[{"id":"C582435","term":"pembrolizumab"},{"id":"D017239","term":"Paclitaxel"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06613360","orgStudyIdInfo":{"id":"CLN-978-SL-101"},"organization":{"fullName":"Cullinan Therapeutics Inc.","class":"INDUSTRY"},"briefTitle":"A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus","officialTitle":"A Phase 1b, Open-label, Pilot Study of CLN-978 for the Treatment of Moderate to Severe Systemic Lupus Erythematosus (SLE)"},"statusModule":{"statusVerifiedDate":"2025-11","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-01-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-09-20","studyFirstSubmitQcDate":"2024-09-23","studyFirstPostDateStruct":{"date":"2024-09-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-11-25","lastUpdatePostDateStruct":{"date":"2025-11-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Cullinan Therapeutics Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE)."},"conditionsModule":{"conditions":["SLE","SLE (Systemic Lupus)"],"keywords":["Systemic Lupus Erythematosus"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":24,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Part A Dose Escalation","type":"EXPERIMENTAL","description":"Patients with SLE treated with CLN-978 in dose escalation cohorts","interventionNames":["Drug: CLN-978"]},{"label":"Part B Further Dose Evaluation","type":"EXPERIMENTAL","description":"Further evaluation of CLN-978 treatment of patients with SLE","interventionNames":["Drug: CLN-978"]}],"interventions":[{"type":"DRUG","name":"CLN-978","description":"Specified dose on specified days","armGroupLabels":["Part A Dose Escalation","Part B Further Dose Evaluation"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Safety and tolerability","description":"Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs)","timeFrame":"48 weeks"}],"secondaryOutcomes":[{"measure":"Pharmacokinetics","description":"Serum concentrations of CLN-978","timeFrame":"48 weeks"},{"measure":"Immunogenicity","description":"Level of anti-drug antibodies","timeFrame":"48 weeks"},{"measure":"Pharmacodynamics-related biomarker","description":"Levels of total B lymphocytes in the peripheral blood","timeFrame":"48 weeks"}],"otherOutcomes":[{"measure":"hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI)","description":"Change in hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) score on a scale of 0 to12 with a higher score meaning worse outcome","timeFrame":"48 weeks"},{"measure":"Physicians Global Assessment","description":"Change in Physicians Global Assessment (PGA) score on a scale of 0 to 3 with a higher score indicating worse outcome","timeFrame":"48 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of SLE at least 24 weeks prior to Screening and meet 2019 EULAR / ACR Classification Criteria at screening.\n* Presence of one or more of the following autoantibodies documented during screening or in the previous 12 months before screening: positive anti-nuclear antibody (ANA) test (≥1:80); anti dsDNA above the upper limit of normal (ULN); anti-Sm above the ULN.\n* Active SLE disease, as demonstrated by a SLEDAI total score ≥6 at screening.\n* Inadequate response to at least 2 of the following treatments: oral corticosteroid, antimalarials, conventional immunosuppressants, or biologics. At least one of the failed treatments should be an immunosuppressive or biologic standard-of care agent.\n* If on corticosteroid and/or antimalarial, the dose must be stable prior to day 1.\n* Laboratory parameters including the following:\n\n  * Absolute lymphocyte count (ALC) ≥0.5 x 109/L\n  * Peripheral B cell count ≥25 cells/µL\n  * Absolute neutrophil count (ANC) ≥1.0 x 109/L\n  * Hemoglobin ≥8 g/dL\n  * Platelet count ≥75 x 109/L.\n  * Estimated glomerular filtration rate (eGFR) (based on CKD-EPI formula) ≥30 mL/min/1.73m2\n  * Total bilirubin ≤1.5 × ULN, except patients with confirmed Gilbert's Syndrome\n  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN\n* Part B only: For patients who were treated in Part A and did not experience dose-limiting toxicity (DLT) or discontinue CLN-978 treatment due to AEs are eligible for retreatment at a higher dose or longer schedule in Part B if they otherwise meet eligibility criteria and at least 90 days have passed since the last dose of CLN-978.\n\nExclusion Criteria:\n\n* Active inflammatory disease other than SLE. Thyroiditis or secondary Sjogren's syndrome is allowed.\n* Considered at high risk for thrombosis.\n* Rapidly progressive glomerulonephritis, and/or urine protein/creatinine \\>3 mg/mg (339 mg/mmol).\n* Active severe neuropsychiatric/CNS manifestations of SLE.\n* Evidence of hepatitis B, hepatitis C (HCV) infection, human immunodeficiency virus (HIV), Epstein-Barr virus (EBV), or cytomegalovirus (CMV) infection.\n* History of splenectomy.\n* Prior treatment with the following:\n\n  * Cellular or gene therapy product directed at any target.\n  * Investigational therapy within 30 days or 5 drug-elimination half-lives (whichever is longer) prior to Day 1.\n  * Any anti-CD19 or anti-CD20 therapy less than 3 months prior to Day 1.\n  * Non-biologic DMARD within 14 days prior to Day 1.\n  * Cyclophosphamide within 1 month or a biologic immunomodulating therapy during 2 months prior to Day 1.\n* Live or attenuated vaccine within 28 days prior to screening or during screening.\n* Active, clinically significant bacterial, viral, fungal, mycobacterial, parasitic, or other infection, including SARS-CoV-2 infection, within 14 days before Day 1.\n* Active or latent tuberculosis (TB) evidenced by a positive or indeterminant Interferon Gamma Release Assay (IGRA), unless the patient has documented previous completion of TB treatment and no current clinical indication of TB.\n* Any condition for which, in the opinion of the Investigator and/or Sponsor, would not be in the best interest of the patient to participate in the study or that could prevent, limit, or confound any protocol-defined assessment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Meagan Sardinha","role":"CONTACT","phone":"+1 617 410 4650","email":"ClinOps@cullinantx.com"}],"locations":[{"facility":"Cullinan Investigative Site","status":"RECRUITING","city":"Avondale","state":"Arizona","zip":"85392","country":"United States","geoPoint":{"lat":33.4356,"lon":-112.3496}},{"facility":"Cullinan Investigative Site","status":"RECRUITING","city":"Tucson","state":"Arizona","zip":"85704","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"Cullinan Investigative Site","status":"RECRUITING","city":"Orlando","state":"Florida","zip":"32808","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Cullinan Investigative Site","status":"RECRUITING","city":"Iowa City","state":"Iowa","zip":"52242","country":"United States","geoPoint":{"lat":41.66113,"lon":-91.53017}},{"facility":"Cullinan Investigative Site","status":"RECRUITING","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Cullinan Investigative Site","status":"RECRUITING","city":"Rochester","state":"New York","zip":"14642","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Cullinan Investigative Site","status":"RECRUITING","city":"Memphis","state":"Tennessee","zip":"38163","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"Cullinan Investigative Site","status":"RECRUITING","city":"Plano","state":"Texas","zip":"75093","country":"United States","geoPoint":{"lat":33.01984,"lon":-96.69889}},{"facility":"Cullinan Investigative Site","status":"RECRUITING","city":"Webster","state":"Texas","zip":"77598","country":"United States","geoPoint":{"lat":29.53773,"lon":-95.11826}},{"facility":"Cullinan Investigative Site","status":"RECRUITING","city":"Salt Lake City","state":"Utah","zip":"84101","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Cullinan Investigative Site","status":"RECRUITING","city":"Parkville","state":"Victoria","zip":"3052","country":"Australia","geoPoint":{"lat":-37.78333,"lon":144.95}},{"facility":"Cullinan Investigative Site","status":"RECRUITING","city":"Victoria Park","zip":"6100","country":"Australia","geoPoint":{"lat":-31.97619,"lon":115.90525}},{"facility":"Arensia Research Clinic","status":"RECRUITING","city":"Tbilisi","country":"Georgia","geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Arensia Research Clinic","status":"RECRUITING","city":"Chisinau","country":"Moldova","geoPoint":{"lat":47.00902,"lon":28.85938}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D008180","term":"Lupus Erythematosus, Systemic"}],"ancestors":[{"id":"D003240","term":"Connective Tissue Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D001327","term":"Autoimmune Diseases"},{"id":"D007154","term":"Immune System Diseases"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT05879744","orgStudyIdInfo":{"id":"CLN-978-001"},"organization":{"fullName":"Cullinan Therapeutics Inc.","class":"INDUSTRY"},"briefTitle":"A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)","officialTitle":"A Phase 1, Open-label, Dose Escalation and Dose Expansion Study of CLN-978 in Patients With Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL)"},"statusModule":{"statusVerifiedDate":"2024-04","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-05-31","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-11","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-04","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-05-05","studyFirstSubmitQcDate":"2023-05-18","studyFirstPostDateStruct":{"date":"2023-05-30","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-04-30","lastUpdatePostDateStruct":{"date":"2024-05-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Cullinan Therapeutics Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL)."},"conditionsModule":{"conditions":["NHL","NHL, Relapsed, Adult"],"keywords":["Relapsed/Refractory B-cell Non-Hodgkin Lymphoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":90,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Part A Dose Escalation","type":"EXPERIMENTAL","description":"Patients with R/R B-NHL treated with CLN-978 in dose escalation cohorts","interventionNames":["Drug: CLN-978"]},{"label":"Part B Dose Expansion","type":"EXPERIMENTAL","description":"Patients with R/R DLBCL, R/R FL and other R/R B-NHL treated with CLN-978 at a dose selected from the Part A Dose Escalation arm.","interventionNames":["Drug: CLN-978"]}],"interventions":[{"type":"DRUG","name":"CLN-978","description":"CD19xCD3 T cell engager","armGroupLabels":["Part A Dose Escalation","Part B Dose Expansion"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Safety and tolerability of CLN-978 based on AEs, AESIs, and SAEs","description":"Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs); incidence of dose interruptions and delays","timeFrame":"24 months"},{"measure":"Define dose regimen for CLN-978","description":"Dose-limiting Toxicities (DLTs)","timeFrame":"24 months"}],"secondaryOutcomes":[{"measure":"Assess preliminary efficacy of CLN-978 by overall response in patients with selective histologies of R/R B-NHL","description":"Overall response rate (ORR)","timeFrame":"24 months"},{"measure":"Assess preliminary efficacy of CLN-978 by complete response in patients with selective histologies of R/R B-NHL","description":"Complete response (CR)","timeFrame":"24 months"},{"measure":"Assess preliminary efficacy of CLN-978 by duration of response in patients with selective histologies of R/R B-NHL","description":"Duration of response (DOR)","timeFrame":"24 months"},{"measure":"Select PK parameters of CLN-978: AUC","description":"Area under-the-concentration-time curve of CLN-978","timeFrame":"24 months"},{"measure":"Select PK parameters of CLN-978: Cmax","description":"Maximum concentration of CLN-978","timeFrame":"24 months"},{"measure":"Select PK parameters of CLN-978: Half-life","description":"Half-life of CLN-978","timeFrame":"24 months"},{"measure":"Immunogenicity of CLN-978 and potential impact on drug exposure","description":"Incidence of anti-drug antibodies to CLN-978","timeFrame":"24 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) PS ≤ 2\n* Documented diagnosis of one of the below CD19+ B-cell neoplasms according to WHO classification (Swerdlow et al., 2016) or WHO classification 2008:\n\n  1. Diffuse large B-cell lymphoma - de novo or transformed\n  2. High-grade B-cell lymphoma\n  3. Primary mediastinal large B-cell lymphoma\n  4. Follicular lymphoma\n  5. Mantle cell lymphoma\n  6. Marginal zone lymphoma (nodal, extranodal, or mucosa-associated)\n* Relapsed, progressive, and/or refractory disease after at least 2 lines of therapy.\n* For Part B expansion cohorts:\n\n  1. Cohort B1: R/R DLBCL that has relapsed after at least 2 prior therapies including a CD20 monoclonal antibody and anthracycline.\n  2. Cohort B2: R/R FL (grade 1-3a) that has relapsed after at least 2 prior therapies including CD20 monoclonal antibody and an alkylating agent.\n  3. Cohort B3: Other R/R B-NHL.\n* Measurable disease defined as ≥1 measurable nodal lesion (long axis \\>1.5 cm and short axis \\>1.0 cm) or ≥1 measurable extra-nodal lesion (long axis \\>1.0 cm) on computed tomography (CT) scan or magnetic resonance imaging (MRI) AND baseline fluorodeoxyglucose-positron emission tomography (FDG-PET) scan demonstrating positive lesion(s) compatible with CT- or MRI-defined anatomical tumor sites.\n* Laboratory parameters including the following:\n\n  1. Lymphocyte count \\< 5 x 10\\^9/L\n  2. Platelet count ≥ 75 x 10\\^9/L\n  3. Absolute neutrophil count ≥ 1.0 x 10\\^9/L; growth factor support allowed in cases of documented bone marrow involvement\n  4. Hemoglobin ≥ 9 g/dL, with or without transfusion\n  5. Creatinine clearance ≥ 45 mL/min\n  6. Total bilirubin ≤ 1.5 × upper limit of normal (ULN), except patients with confirmed Gilbert's Syndrome\n  7. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN (unless attributed to hepatic involvement by lymphoma)\n\nExclusion Criteria:\n\n* Primary CNS lymphoma or known CNS involvement by lymphoma at study screening\n* Known past or current malignancy other than the inclusion diagnosis\n* Known clinically significant cardiac disease\n* Significant central nervous system disease\n* Prior organ allograft\n* Confirmed history or current autoimmune disorder or other disease requiring ongoing immune suppression\n* Active Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), or known Human Immunodeficiency Virus (HIV) infection\n* Live virus vaccines within 28 days of the first dose of CLN-978, during treatment, and until the end of last dose of CLN-978\n* Known active, clinically significant bacterial, viral, fungal, mycobacterial, parasitic, or other infection, including coronavirus disease of 2019 (COVID-19) infection, at the time of enrollment or within 7 days of the first dose of CLN-978.\n* Prior treatment with any of the following:\n\n  1. Allogeneic HSCT\n  2. Autologous HSCT within 30 days prior to the first dose of CLN-978\n  3. Chimeric antigen receptor T cell therapy (CAR-T) within 30 days prior to the first dose of CLN-978\n  4. Any investigational CD19 x CD3 T cell engager (TCE)\n  5. Unconjugated CD19 monoclonal antibody ≤ 4 weeks prior to the first dose CLN-978\n  6. Radio-conjugated or CD19 antibody-drug conjugate ≤ 12 weeks prior to the first dose CLN-978\n  7. Investigational or standard of care monoclonal antibodies, chemotherapy, or other investigational agent ≤ 4 weeks or 5 half-lives, whichever is shorter, prior to the first dose of CLN-978\n  8. Radiation therapy (XRT), with the exception of focal treatment for symptom control, ≤ 4 weeks of the first dose of CLN-978\n* Woman of child-bearing potential who is pregnant, breast-feeding, or plans to become pregnant\n* Male patients who plan to father a child or donate sperm within 120 days of last study drug administration","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"University of Alabama at Birmingham","city":"Birmingham","state":"Alabama","zip":"35294","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"City of Hope","city":"Duarte","state":"California","zip":"91010","country":"United States","geoPoint":{"lat":34.13945,"lon":-117.97729}},{"facility":"Winship Cancer Institute at Emory University","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Massachusetts General Hospital","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Hackensack University Medical Center","city":"Hackensack","state":"New Jersey","zip":"07601","country":"United States","geoPoint":{"lat":40.88593,"lon":-74.04347}},{"facility":"University of Texas Southwestern Medical Center","city":"Dallas","state":"Texas","zip":"75390","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D008228","term":"Lymphoma, Non-Hodgkin"},{"id":"D012008","term":"Recurrence"},{"id":"D016393","term":"Lymphoma, B-Cell"}],"ancestors":[{"id":"D008223","term":"Lymphoma"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D008232","term":"Lymphoproliferative Disorders"},{"id":"D008206","term":"Lymphatic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D007160","term":"Immunoproliferative Disorders"},{"id":"D007154","term":"Immune System Diseases"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":false}
]}